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1. Introduction 
Clostridium difficile infection (CDI) is the most common infectious cause of healthcare-
acquired diarrhoea. Approximately 15%–25% of all cases of antibiotic-associated colitis 
(AAC) are caused by C. difficile  and this likelihood increases with the severity of disease, 
reaching 95%–100% among patients with documented antibiotic-associated 
pseudomembraneous colitis (PMC) (Bartlett, 1994). Since the initial report of C. difficile as the 
cause of AAC in 1978 (Larson et al., 1978), subsequent work has provided important 
information regarding risk factors, diagnosis and effective therapy. More recently, 
significant challenges have arisen due to increases in frequency and severity of disease, 
limitations of standard therapy and propensity for recurrence of infection. There has been 
an unanticipated increase in morbidity and mortality attributed to this disease, linked in 
part to the emergence of antimicrobial-resistance and the epidemic bacterial strain, BI/NAP-
1/ribotype 027 leading to a resurgence of CDI as a major cause of hospital-acquired 
infection.  
2. Clinical presentation of CDI 
Infection with C. difficile can result in clinical manifestations ranging from asymptomatic 
carriage to fulminant colitis and death (Bartlett, 1994). The pathogenesis of symptomatic 
CDI is characterised by an acute intestinal inflammatory response, prominent neutrophil 
infiltration and associated tissue injury (Savidge et al., 2003). Features of severe CDI include  
pseudomembranes visible on endoscopy, abdominal cramps, fever, marked increase in 
white cell count, rise in serum creatinine level and hypoalbuminemia (Cloud et al., 2009; 
Pepin et al., 2009). Systemic symptoms may be absent in mild disease but are common in 
moderate or severe disease. Accurate diagnosis early in the disease course is important for 
the successful management of CDI.  
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2.2 Elevated white cell count and hypoalbuminemia 
The increase in white cell count associated with CDI is mainly a result of a marked increase 
in peripheral blood neutrophils. The intense intestinal inflammatory response in severe CDI 
may also result in fever, abdominal pain, thickening of the colon and paralytic ileus that can 
evolve into toxic megacolon. Profuse watery diarrhoea may also be associated with nausea, 
vomiting, dehydration or lethargy, in addition to severe hypoalbuminemia (serum albumin 
<35g/L) as a result of protein losing enteropathy (Sunenshine & McDonald, 2006).  
2.1 Pseudomembraneous colitis  
Pseudomembranes are characterised as discrete plaques of yellow-white exudate <10mm 
diameter separated by normal or mildly hyperaemic mucosa usually restricted to the colon, 
with occasional cases involving the small intestine (Figure 1A &B). These may progress to 
form a membraneous exudate covering a large degree of the colonic epithelial surface. 
Ulceration into the sub-mucosa can result in severe cases. The lesions are characterised 
histologically as discrete regions of necrotic surface epithelium with accumulation of fibrin, 
mucous and cell debris (Pothoulakis, 1996). Polymorphonuclear cells and neutrophils 
infiltrate into the lesion exudate and the underlying lamina propria from the systemic 
bloodstream (Kelly et al., 1994a). Later stage lesions involve the superficial mucosa and 
crypts and further infiltration of polymorphonuclear cells and eosinophils. Lesions coalesce 
to create plaques covering larger areas of the mucosa. Rare complications involve deep 
necrosis and ulceration of the colon sub-mucosa which can lead to perforation, septicaemia 
and death.   
 
Fig. 1. (A) Pseudomembraneous colitis as confirmed by sigmoidoscopy. Discrete yellow 
plaques indicate the ulcerated lesions. (B) Histopathological features of 
pseudomembraneous colitis include loss of crypt structure, infiltration of 
polymorphonuclear cells and surface accumulation of fibrin, mucous and necrotic cell 
debris. 
3. Risk factors 
The major risk factors for CDI are increasing age, prolonged hospital stay and recent or 
current antimicrobial use. The most important risk factor is alteration of bowel microflora 
and subsequent loss of colonisation resistance associated with antimicrobial usage within 
BA 
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the previous 2-3 months prior to infection (Bignardi, 1998; Dial et al., 2008). There are 
particular classes of antimicrobials that are associated with the highest risk of C. difficile 
acquisition, including clindamycin, cephalosporins and ǃ-lactam antimicrobials and more 
recently fluoroquinolones (Owens et al., 2008). Recent outbreaks involving a particular 
epidemic strain of C. difficile have been predominantly associated with fluoroquinolone 
usage (Loo et al., 2005; Pepin et al., 2005). The risk of developing CDI increases with the use 
of multiple antibiotics and prolonged duration of therapy. 
In addition to these traditional risk factors, other factors associated with CDI include; 
underlying comorbidities, including inflammatory bowel disease (IBD), gastrointestinal 
procedures and exposure to an environment contaminated with toxigenic C. difficile, usually 
via hospitalisation (Johnson & Gerding, 1998). Proton pump inhibitors have been associated 
with CDI risk but their use is often a marker of the severity of underlying disease, which is 
in itself a strong risk factor for CDI (Kyne et al., 2000; Kyne et al., 2001). 
The host immune status is also important in determining the outcome of colonisation with 
C. difficile. Immuno-compromised patients are at increased risk for CDI (Yolken et al., 1982) 
as are patients with a poor immune response to C. difficile toxins (Kyne et al., 2000; Mulligan 
et al., 1993). The role of protective host immunity in determining progression and severity of 
CDI, specifically the inability to mount an adequate colonic IgA and or serum IgG response 
to C. difficile toxins will be discussed further. 
The incidence of CDI acquired in the community appears to be increasing. Cases have also 
been reported in which there has been no recorded exposure to antibiotics or recent 
hospitalisation. Similarly an increasing number of cases of CDI are occurring in lower age 
groups and children. This may be due to the emergence of a new strain that is more 
commonly associated with animal and non-hospital sources of infection, but this has yet to 
be fully substantiated (Goorhuis et al., 2008). 
4. Microbial virulence factors 
4.1 Toxins A and B 
The major virulence factors of toxigenic Clostridium difficile are two large protein toxins A 
(TcdA) and B (TcdB) that have both been shown to be responsible for the profound 
intestinal inflammatory response seen in CDI (Kuehne et al., 2010; Thelestam & Chaves-
Olarte, 2000). Toxins A and B are very similar in structure, with three functional domains: a 
receptor binding domain, a translocation domain and a catalytic domain involved in 
binding to the host cell, entry into the cytoplasm and inactivation of Rho GTPases 
respectively (von Eichel-Streiber et al., 1996). 
Most disease-causing C. difficile strains produce both toxins, encoded by the pathogenicity 
locus (PaLoc) (Braun et al., 1996; Rupnik et al., 2005). Genetic variations in the toxin genes 
leads to strains of different ‘toxinotypes’(Rupnik, 2008). Most variation across toxinotypes is 
seen in the binding domain of toxin A, which can lead to so called TcdA-TcdB+ strains 
which have been found to demonstrate comparable cytotoxicity to normal toxin-producing 
strains and have been involved in clinical outbreaks (Drudy et al., 2007). Up to 31 different 
toxinotypes have been identified so far (Rupnik, Feb 2011), highlighting the possibility of a 
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wide variety of C. difficile toxin protein structures and cytotoxic activities. Infection with 
non-toxigenic strains that do not possess the pathogenicity locus can occur and is usually 
thought to result in asymptomatic colonisation. 
The PaLoc also contains genes involved in regulation of transcription of the toxins (Braun et 
al., 1996; Rupnik et al., 2005). The epidemic strain BI/NAP-1/ribotype 027 has been shown 
to contain an 18bp deletion in one of these regulatory genes, tcdC, which results in increased 
toxin production (Dupuy et al., 2008). This is thought to contribute to the virulence of this 
strain and its involvement in recent epidemics (Warny et al., 2005). 
Toxins A and B mediate their cytopathic effect by disrupting the cytoskeleton of intestinal 
epithelial cells and causing tight junctions to open, resulting in loss of integrity of the 
protective monolayer (Figure 2).  
Once the intestinal epithelium is breached, the toxins are able to access the underlying 
lamina propria and come into contact with resident macrophages and circulating peripheral 
blood mononuclear cells (Pothoulakis, 2000; Thelestam & Chaves-Olarte, 2000). 
C. difficile toxins are also capable of inducing the release of several classes of cytokines and 
neuroimmune pro-inflammatory mediators such as interleukin-8 (Il-8) and tumour necrosis 
factor-ǂ (TNF- ǂ) from intestinal epithelial cells, macrophages and mast cells. These recruit 
circulating inflammatory cells such as neutrophils into the site of infection and perpetuate 
the inflammation and fluid secretion associated with CDI (Pothoulakis, 2000). 
 
Fig. 2. The role of C. difficile toxins A and B in mediating the host inflammatory response  
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In addition to the indirect effect of the toxins on cells of the immune system, C. difficile toxin 
A has also been shown to directly bind to peripheral blood mononuclear cells, most notably 
monocytes and induce cell death by apoptosis (Modi et al., 2011; Solomon et al., 2005). This 
highlights the essential role that toxins play in initiating and prolonging bacterial infection 
by inactivating key elements of the host protective immune response.  
4.2 Binary toxin 
In addition to toxins A and B, a further toxigenic component, binary toxin, is expressed in a 
subset of toxigenic C. difficile strains, most notably the epidemic BI/NAP-1/ribotype 027 
strain (Rupnik, 2008; Stubbs et al., 2000). Although possessing an ADP-ribosylation function 
and cytotoxic activity against mammalian cell lines, the role of binary toxin in disease is 
unclear (Geric et al., 2006). 
4.3 Surface layer proteins 
In addition to the major secreted toxins, the vegetative C. difficile bacterium produces other 
potential virulence factors. Surface layer proteins are considered to play a vital role in 
colonisation of the gut and bacterial adherence to the mucosa. They are also important 
immunogens and can induce the host inflammatory and antibody response (Ausiello et al., 
2006; Calabi et al., 2002; Drudy et al., 2004; Pechine et al., 2005). As seen with the toxin 
proteins, surface layer proteins can be highly variable, particularly surface layer protein A 
(SlpA) resulting in varying degrees of bacterial adherence ability.  
4.4 Flagella 
Flagella are also major bacterial virulence factors that enable chemotaxis and penetration of 
the mucus layer and direct adherence of the bacterium to the epithelial cell surface for 
localised secretion of toxins. Pathogenic C. difficile strains display a range of flagella proteins 
and subsequent adhesion capabilities (Tasteyre et al., 2001). The immunogenic potential of 
flagellin is widely appreciated and specific Toll-like receptors (TLRs) are present on the 
epithelial cell surface to detect flagellin as part of the host cell sensing of pathogens. 
5. Host factors that influence outcome of infection 
The host’s ability to respond to C. difficile virulence factors plays a major role in determining 
the outcome of colonisation with this organism. Infection with the same toxigenic strain can 
result in a variety of outcomes, including asymptomatic carriage through to symptomatic or 
severe disease. Certain intrinsic host features, including toxin receptor density (Eglow et al., 
1992) and presence or absence of barrier flora (Borriello, 1990) are important in the initial 
stages of colonisation, however early host detection of infection and initiation of an 
appropriate immune response likely plays a role in preventing prolonged and severe 
disease and in providing protection from recurrence of infection.  
5.1 Host protective microflora 
The most important risk factor for the development of CDI is antimicrobial use, which leads 
to alteration of the commensal gut microflora and loss of colonisation resistance, enabling 
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unrestricted growth of toxigenic C. difficile. It is proposed that the healthy gut microflora 
affords resistance by physical inhibition of pathogen adhesion to the mucosa, blocking 
production of microbial toxins, competition for nutrients and stimulation and development 
of the mucosal immune system (Mazmanian et al., 2005; Weinstein & Cebra, 1991).  
Recent metagenomic studies have provided a detailed insight into the various bacterial 
species groups involved in host protection against C. difficile and have identified an 
important role for members of the Bifidobacterium and Bacteroides species (Hopkins & 
Macfarlane, 2002; Hopkins et al., 2002) Bacterial species diversity was markedly lower in CDI 
patients and consisted of a higher number of facultative anaerobes than in healthy controls 
(Hopkins & Macfarlane, 2002).  
Healthy resident faecal microflora have been shown to directly suppress the growth of C. 
difficile introduced in vivo, possibly through production of volatile fatty acids and bacterial 
metabolic by-products (Rolfe, 1984). This may explain how approximately 5% of 
asymptomatic healthy adults carry low concentrations of C. difficile in their colon. They have 
been  shown in vitro to be held in check by normal gut flora (Fekety & Shah, 1993).  Non-
toxigenic strains of C. difficile may colonise the gut and prevent infection with toxigenic 
strains (Borriello & Barclay, 1985; Sambol et al., 2002) and even asymptomatic colonisation 
with toxigenic strains has been associated with a decreased risk of CDI (Shim et al., 1998).  
The precise mechanisms by which asymptomatic colonisation is able to protect against CDI 
have yet to be defined, however continuous immunological challenge with C. difficile bacterial 
peptides and/or low levels of toxins may prime the immune system to act efficiently in 
response to a subsequent infection (Viscidi et al., 1983). The commensal microflora has also 
been shown to profoundly influence the development of the humoral components of the gut 
immune system, influencing IgA production by B cells (Weinstein & Cebra, 1991).  
5.2 The innate immune response 
0 – 12 hours post-infection 
C. difficile toxins act quickly to breach the protective mucosal barrier in order to release 
nutrients for bacterial growth in to the lumen. The host needs to respond rapidly to 
circumvent further cellular damage and possible dissemination of toxins into the sub-
mucosa and bloodstream. The early host pro-inflammatory response or inducible innate 
immune response is stimulated initially by the epithelial cells, the first and major cell type 
encountered by microorganisms in the mucosa. 
The intestinal epithelium has developed a wide array of protective mechanisms to prevent 
bacterial adherence and maintain the integrity of the monolayer, including mucous secretion 
and tight junctions. Epithelial cells are also able to sense pathogen-associated molecules 
such as LPS, peptidoglycan and flagellin via specific cell surface TLR receptors. Epithelial 
cells intoxicated by C. difficile release pro-inflammatory mediators including Interleukin-8 
(Il-8) and macrophage inflammatory protein-2 (MIP-2) into the underlying lamina propria 
(Flegel et al., 1991; Mahida et al., 1998).  
The sub-mucosal macrophages, monocytes and dendritic cells then disseminate the 
inflammatory cascade, via the further release of pro-inflammatory cytokines and 
neuropeptides that recruit peripheral blood cells to the site of infection (Pothoulakis, 1996). 
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The combined action of cytokines and histamine increases permeability of the vascular 
endothelium causing fluid leakage and the symptomatic profuse watery diarrhoea 
associated with C. difficile infection. The expression of specific monocyte and leucocyte-
adhesion molecules, including CD18 integrins and selectins are upregulated and enable 
migration of leukocytes and monocytes towards the site of cytokine release (Kelly et al., 
1994a). Phagocytosis and digestion of the bacteria with lysozyme, collagenase and 
peroxidise promotes clearance of the infection, but contributes to the extensive cellular 
necrosis characterised by the pseudomembraneous plaques. 
5.3 The adaptive immune response 
1 – 12 days post infection 
The importance of the adaptive immune response in influencing the outcome of C. difficile 
colonisation has been appreciated for many years (Aronsson et al., 1985; Johnson et al., 1992; 
Warny et al., 1994), however the contributions that individual immunoglobulin classes play 
in protection and prevention have taken longer to elucidate. 
An initial challenge with C. difficile (irrespective whether this is associated with symptoms 
or not) will stimulate the maturation and multiplication of naive B-cells, generating 
antibody-producing plasma cells and specific memory B-cells. The process of 
immunoglobulin class switching is then induced by specific cytokines, to ensure that the full 
range of immunoglobulin classes are generated in response to specific C. difficile antigens. It 
is likely that the initial immune challenge occurs in infancy, as approximately 60% of 
healthy non-colonised or asymptomatic adults have detectable serum IgG and IgA 
antibodies to C. diffiicle toxins (Kelly et al., 1992; Sanchez-Hurtado et al., 2008; Viscidi et al., 
1983).  
Certain immunoglobulin classes are more important than others in mediating immunity to 
C. difficile. IgA is mainly associated with the gut mucosa and prevention of pathogen 
colonisation, whereas IgM is released first in infection, followed by IgG, which provides the 
major protection against pathogens (Underdown & Schiff, 1986). A selective reduction in 
mucosal IgA has been shown to be associated with severe CDI and reduction in colonic IgA 
producing cells may predispose to recurrence of infection (Johal et al., 2004).  
Serum anti-toxin antibody levels have been found to play an important role in determining 
the outcome of colonisation and protection against CDI recurrence. Patients who are 
asymptomatically colonised with C. difficile have higher serum anti-toxin A IgG levels than 
colonised patients who develop diarrhoea (Kyne et al., 2000). This suggests that high anti-
toxin A IgG levels at the time of colonistion protect against CDI. 
Once colonisation has progressed to CDI, serum IgM and IgG antibody responses to C. 
difficile toxins A, B and non-toxin antigens have been shown to be higher in patients who 
experience a single episode of CDI compared to patients with recurrent CDI (Kyne et al., 
2001). The importance of varying antibody levels during the course of infection was also 
highlighted, as early IgM responses and later IgG responses (day 3 and day 12 post onset of 
diarrhoea respectively) were significantly higher in those patients who did not experience 
recurrence of CDI (Kyne et al., 2001). Deficiency in certain subclasses of IgG (IgG2 and IgG3) 
has also been found to be related to recurrence of disease (Katchar et al., 2007). A high 
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natural anti-toxin antibody response does not always however protect from symptomatic 
CDI. Patients who are critically ill are less likely to be protected than those who are less 
severely ill, despite similar antibody levels (Kyne et al., 2000). This suggests that other host 
factors are also important in immune protection and should be considered when predicting 
outcome of colonisation on host immune status alone. 
Immunity to C. difficile surface layer proteins (SLP’s) would be expected to provide 
important protection during bacterial colonisation and prevention of symptomatic CDI. 
IgM, IgA and IgG antibody levels to SLP’s were shown to be similar in control patients, 
asymptomatic carriers and CDI patients, however a lower anti-SLP IgM response was 
observed in patients with recurrent CDI compared to patients with a single episode of CDI 
(Drudy et al., 2004). A separate study showed that anti-SLP IgG levels in patients with CDI 
and asymptomatic carriers were higher compared to levels in control patients without CDI 
(Sanchez-Hurtado et al., 2008). 
C. difficile bacterial flagellar proteins FliC and FliD, and the other surface-associated proteins 
expressed during the course of infection, have also been shown to be immunogenic. 
Antibodies against these proteins may be detected after CDI diagnosis and for at least 2 
weeks following diagnosis (Pechine et al., 2005).  
5.4 Genetic predisposition to infection: Il-8 promoter mutations 
Mucosal Il-8 and neutrophil recruitment have been shown to be essential for the 
pathogenesis of CDI and subsequent amplification of the acute inflammatory response. In 
particular, the neutrophil response to C difficile toxins is likely to play a role in determining 
the severity of CDI.  
C. difficile toxins induce monocytes and epithelial cells to produce Il-8, by increasing binding 
of nuclear factors to the Il-8 promoter and up-regulating transcription of the Il-8 gene 
(Linevsky et al., 1997). Some patients may have a genetic pre-disposition to severe CDI due 
to a single nucleotide polymorphism (SNP) in the Il-8 gene promoter. The presence of an AA 
(rather than AT or TT) genotype at position −251 has been shown to be associated with 
increased susceptibility to C. difficile toxins and increased fecal Il-8 levels (Jiang et al., 2006; 
Jiang et al., 2007). The Il-8 promoter AA genotype SNP is also associated with the lack of a 
protective adaptive antitoxin A antibody response in hospital patients with CDI (Jiang et al., 
2006; Jiang et al., 2007).  
6. Treatment strategies for CDI  
6.1 Antimicrobial therapy 
Non-severe CDI can be treated initially with metronidazole for 10-14 days (ASHP, 1998). For 
severe disease, vancomycin treatment for 10 -14 days is suggested. Reliance on antimicrobial 
agents for treatment of C. difficile infection would be expected to further damage the host 
microflora, increasing the risk of recurrence. Recurrence can occur in up to 25% of cases 
(Kelly et al., 1994b) and may be due to persistence of initial infection after treatment or re-
infection. Treatment for recurrences may follow vancomycin administration in a pulsed 
regimen (Mc Farland et al., 2002) that allows the germination of spores in between 
antimicrobial administration to improve efficacy. Other antibiotics, nitazoxanide, 
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teicoplanin and most recently fidaxomicin have been shown to be as effective as 
vancomycin treatment and have been indicated as possible alternative therapies (de Lalla et 
al., 1992 ; Louie et al.; Musher et al., 2009). 
Non-antimicrobial approaches to management of CDI and in preventing colonisation, such 
as immune-mediated therapy would limit the effect on the gut microflora, lessening the risk 
of replapse. 
Currently available antimicrobial and non-antimicrobial therapies in use for management of 
CDI and those under development are outlined in Table 1. 
 
 Currently used Under development 
Antimicrobial agents Metronidazole Ramplanin 
 Vancomycin 
Nitazoxanide 
Teicoplanin 
 
 Fidaxomicin  
Non-antimicrobial agents   
Toxin neutralising agents Cholestyramine 
 
Bovine whey protein 
‘Mucomilk’ 
Tolevamer 
Biotherapeutic agents Saccharomyces boulardii 
Fecal transplants 
Non-toxigenic C. difficile 
Immune-mediated agents Intravenous 
immunoglobulin 
(IVIG) 
Human monoclonal antibodies 
(HuMabs) 
Toxoid vaccines (Toxins A & B) 
Active vaccines (SLP, flagella 
antigens) 
Table 1. Treatment strategies for the management of CDI 
7. Immune-mediated therapy 
An effective antibody response to C. difficile toxins and non-toxin antigens is important in 
influencing the outcome of colonisation and symptomatic CDI and provides the basis for the 
development of antibody-mediated therapeutics and vaccines. An overview of 
immunisation strategies in CDI treatment and prevention has been examined in various 
studies and is reviewed below and illustrated in Figure 3.  
7.1 Passive immunisation therapy 
Passive immunotherapy, involving the direct transfer of antibodies has been studied in both 
humans and animals and has mainly focused on antibodies against C. difficile toxins A and B  
7.1.1 Animal studies 
Oral and parenteral administration of bovine anti-toxoid immunoglobulin concentrate (BIC) 
has been shown to prevent diarrhoea and death in both the hamster and mouse models of 
CDI (Kelly et al., 1996; Lyerly et al., 1991). Similarly, hen IgY antibodies to recombinant 
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peptides of both toxins A an B have also been shown to  prevent diarrhoea or death when 
administered orally to hamsters (Kink & Williams, 1998). 
Parenteral immunisation with monoclonal antibodies against the binding region of toxin A 
was able to protect gnotobiotic mice from diarrhoea and death following toxigenic C. difficile 
challenge (Corthier et al., 1991).  The best protection against CDI and recurrence is however 
afforded by combination therapy with neutralising antibodies against both toxins A and B. 
Human monoclonal antibodies (HuMabs) have been developed after immunisation of 
human immunoglobulin gene transgenic mice with inactivated toxins A and B (Babcock et 
al., 2006). Intraperitoneal administration of anti toxin A and B HuMabs protected hamsters 
from mortality and recurrence of CDI. 
 
Fig. 3. An overview of immunisation, both active and passive and vaccination against C. 
difficile. 
7.1.2 Human studies 
Initial studies examining the efficacy of oral administration of bovine immunoglobulin (BIC) 
in preventing or treating human CDI were promising, but have not progressed further 
(Kelly et al., 1996; Warny et al., 1999). Bovine anti-C. difficile IgA purified from the milk of 
immunised cows (Mucomilk) was also found to be highly effective at reducing recurrent 
human CDI, but studies were also not continued further (Mattila et al., 2008; van Dissel et al., 
2005). 
Antibiotics:    Metronidazole 
                        Vancomycin 
                        Fidaxomicin 
Oral passive immunisation: 
Human monoclonal 
antibodies (HuMabs) 
LUMEN 
LAMINA PROPRIA 
IVIG 
Intravenous passive immunisation: 
Plasma cell activation  
Bovine 
secretory IgA 
Host immunoglobulin 
release 
HuMabs 
Anti-CD18 antibodies  
Anti-inflammatory agents  
Active immunisation:  
Toxoid  
Recombinant 
polypeptides  
www.intechopen.com
Clostridium difficile-Associated Colitis: 
Role of the Immune Response and Approach to Treatment 
 
75 
Intravenous immunisation with pooled anti-toxin A and B IgG immunoglobulin (IVIG) has 
been the most widely studied mode of passive immunotherapy in humans (Abougergi et al., 
2010; O'Horo & Safdar, 2009; Wilcox, 2004). Administration of IVIG to children with low 
antitoxin antibody levels and relapsing CDI resulted in an increase in antibody levels and 
subsequent resolution of CDI (Leung et al., 1991). IVIG has also been used for the treatment 
of severe or refractory CDI with varying success. There is a lack of consensus regarding the 
optimal dose (150 – 400mg/kg) and dosing regimen (1-3 doses) of IVIG. The lack of 
randomised controlled clinical trials for IVIG and an association with increased mortality 
when administered to critically ill patients with CDI in observational studies has served to 
limit its attractiveness as a possible therapy (Abougergi et al., 2010). 
 Passive intravenous immunotherapy with HuMabs against toxins A and B has been shown 
to be well tolerated and effective in protecting patients from recurrence of CDI (Babcock et 
al., 2006; Leav et al., 2010; Lowy et al., 2010). When used in symptomatic CDI patients in 
conjunction with standard antimicrobial therapy, recurrence rates were reduced by 72%, 
although severity of symptoms was not reduced (Lowy et al., 2010). The circulating HuMabs 
provided protection from subsequent challenge or recurrence due to a half-life of up to 26 
days. A role for HuMabs in reducing symptomatic CDI is less well defined however they 
may be useful as prophylaxis for patients at high risk of infection or in enabling clearance of 
persistent infection.  
7.2 Active immunisation/vaccination 
As soon as the importance of C. difficile toxins in initiating symptomatic infection was 
appreciated, studies into active immunisation with inactivated toxin protein toxoids as a 
means of protecting from CDI were carried out (Kim et al., 1987; Libby et al., 1982).   
7.2.1 Animal studies 
Hamsters vaccinated with formalin-inactivated C. difficile culture filtrate by combined 
parenteral and mucosal immunisation were found to be protected from CDI (Torres et al., 
1995). Similarly, parenteral administration of a toxoid vaccine to hamsters induced high 
serum levels of anti-toxin A and B antibodies that mediated immune protection against 
diarrhoea and death (Giannasca et al., 1999). Anti-toxin antibodies were therefore confirmed 
as the major mediators of the protective response. 
Vaccination of mice via transcutaneous administration of a toxin A toxoid derivative  and 
cholera toxin as an immunoadjuvant also showed good induction of anti-toxin A IgG 
antibodies (Ghose et al., 2007). 
Subsequent studies have focused on the use of recombinant polypeptides from toxin A, 
thought at the time to be the main toxin mediator of intestinal injury in CDI. Immunisation 
with recombinant toxin A binding domain polypeptides was shown to partially protect 
hamsters against CDI, and induced a systemic neutralizing immune response in mice, when 
administered with an E. coli toxin adjuvant (Lyerly et al., 1990; Ward et al., 1999). Oral 
immunisation with an attenuated Vibrio cholerae live vector modified to express a fusion 
protein of the binding domain of toxin A was also shown to induce effective immunity 
against toxin A in rabbits (Ryan et al., 1997).  A DNA vaccine against the binding domain of 
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toxin A has also been developed for human use. It was shown in a trial to be successfully 
expressed in host mice cells and induced the production of neutralising antibodies and 
protected from death (Gardiner et al., 2009).  
7.2.2 Human studies 
Only one candidate C. difficile vaccine has progressed to human trials. A formalin-
inactivated toxin A and B toxoid vaccine was safely tolerated in healthy individuals after 
intramuscular administration and was shown to induce high serum anti-toxin antibody 
levels (Aboudola et al., 2003; Kotloff et al., 2001). When used to treat patients with recurrent 
CDI, the vaccine was also successful (Sougioultzis et al., 2005). Phase II clinical trials of a C. 
difficile toxoid vaccine are currently in progress. It is thought that this vaccine would be most 
cost effective when targeted at those at high-risk of developing CDI and in preventing 
recurrence thereby reducing the economic burden of C. difficile disease (Lee et al., 2010). 
7.3 Innate immunity-mediated therapy 
The inflammatory response to CDI is mediated in the early stages by the innate immune 
response, most notably the release of Il-8 from intoxicated epithelial cells and the infiltration 
of neutrophils from the bloodstream. Pre-treatment of rabbits with monoclonal anti-CD18 
antibodies was found to protect from severe inflammation and tissue necrosis, by 
preventing neutrophils from migrating across the vascular endothelium (Kelly et al., 1994a). 
C. difficile toxins would still be able to cause intestinal epithelial damage in anti-CD18-
treated patients via triggering infiltration of other inflammatory cells including monocytes 
and mast cells via Il-8 release from intoxicated intestinal epithelial cells. Amplification of the 
inflammatory response by neutrophils however would be greatly reduced. The symptoms 
of CDI in anti-CD18-treated patients would therefore be expected to be less severe and 
disease may resolve independently of treatment. 
Inflammatory mediators have also been shown to reduce intestinal injury in CDI by 
blocking  signals that perpetuate the inflammatory cascade (Kim et al., 2007; Kokkotou et al., 
2009). Their use in conjunction with antibiotics or other therapies may be more effective in 
the most severe CDI cases. 
8. Future strategies for prevention and treatment of CDI 
Vaccination strategies currently under trial focus on inducing an immune response to C. 
difficile toxins A and B, however colonisation is the first step in pathogenesis. Other C. 
difficile targets, such as surface layer proteins and flagella antigens that have been developed 
as vaccine antigens to inhibit colonisation have proven to reduce C. difficile colonisation in 
mice and hamsters, but did not prevent it completely (Brun et al., 2008; Ni Eidhin et al., 2008; 
Pechine et al., 2007). Widespread vaccination against C. difficile would be expected to reduce 
bacterial carriage and therefore spread of the organism, but may serve to inadvertently 
reduce other protective members of the Clostridium spp. in the gut microflora leading to 
unanticipated side-effects.  
Development of toxoid vaccines against both toxin A and B should also take into account 
the variety in toxin protein structures exhibited by the 31 toxinotypes currently identified. 
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All vaccines currently under trial are based on inactivated toxoids from a reference strain of 
C. difficile (Aboudola et al., 2003; Sougioultzis et al., 2005), therefore would in theory only 
protect immunised patients from a proportion of the possible toxin proteins that would be 
encountered in infection with multiple strain types. This limited cross-reactivity could be 
further reduced in vaccines where recombinant polypeptides from the cell-binding domain 
have been used. This would be most important in recurrent cases, where a small proportion 
of patients can be infected with a different strain type to their initial infection, rather than re-
infection or lack of clearance of their existing colonising strain. 
The impact of aging on the efficient functioning of the immune system is also under-
investigated with respect to CDI. Older patients are most at risk of developing CDI and 
therefore are the population most likely to be targeted for vaccination. Due to immune 
senescence many older patients may not mount an adequate antibody response to 
vaccination (Burns, 2004).  
9. Conclusions 
The outcome of C. difficile infection, whether it is asymptomatic colonisation or fulminant 
colitis, is mediated at every stage by the host immune system. The innate immune response 
plays the foremost role in CDI-induced inflammation and tissue injury, whilst the adaptive 
immune response mainly mediates protection, either from initial infection or subsequent 
recurrence. The most effective therapies against C. difficile would therefore augment a 
specific immunoglobulin response whilst suppressing the innate response that triggers 
neutrophil migration into the mucosa. Vaccine targets developed to protect the at-risk 
population have shown initial efficacy, however further trials are needed to determine 
whether they have the widespread cross-reactivity needed to protect patients from all 
possible strains of C. difficile. It also remains to be seen whether the majority of older patients 
will be able to mount an immune response of a sufficient magnitude to the vaccine, to 
provide adequate protection.  
Until these conditions are met, antimicrobials (metronidazole, vancomycin and the newly 
FDA-approved Fidaxomicin) remain the mainstay of CDI treatment despite their limitations. 
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